Research Topics
| Delong LiuSummaryAffiliation: New York Medical College Country: USA Publications
| Collaborators
|
Detail Information
Publications
The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivoLulu Lu
Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
Oncol Rep 16:1363-7. 2006..In conclusion, PHI induced apoptosis and inhibited the growth of xenografts by targeting the cell cycle regulators. PHI induced selective apoptosis effects in the rapidly growing tumor cells but not in the normal tissues...
t(8;14;18): a 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemiaDelong Liu
Division of Oncology Hematology, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
Mol Cancer 6:35. 2007..Dual translocation of t(8;14) (c-myc) and t(14;18) (bcl-2) was reported to be associated with extremely poor prognosis. This study reports a novel t(8;14;18) triple translocation in two patients with Burkitt's lymphoma...- B-Raf and the inhibitors: from bench to bedsideTiangui Huang
Division of Hematology and Oncology, Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA
J Hematol Oncol 6:30. 2013..This review also discussed the current understanding of B-Raf signaling mechanism, methods of mutation detection, treatment strategies as well as potential methods of overcoming therapeutic resistance... - MEK and the inhibitors: from bench to bedsideAkintunde Akinleye
Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, 10595, USA
J Hematol Oncol 6:27. 2013..This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330... - CD19: a biomarker for B cell development, lymphoma diagnosis and therapyKemeng Wang
Division of Hematology and Oncology, Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
Exp Hematol Oncol 1:36. 2012..This review also summarized latest clinical development of CD19 antibodies, anti-B4-bR (an immunotoxin conjugate), blinatumomab (BiTE), and SAR3419 (huB4-DM4), a novel antibody-drug conjugate... - Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysisShamudheen M Rafiyath
Division of Hematology and Oncology, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
Exp Hematol Oncol 1:10. 2012..abstract:.. - Current management and prognostic features for gastrointestinal stromal tumor (GIST)Gurpreet Lamba
Division of Oncology Hematology, New York Medical College and Westchester Medical Center, Valhalla, NY, 10595, USA
Exp Hematol Oncol 1:14. 2012..Indications for neoadjuvant and adjuvant therapy along with duration of therapy are also explained. A brief discussion of latest biomarkers and updates from recent meetings is also provided... - Novel CD20 monoclonal antibodies for lymphoma therapyShundong Cang
Department of Oncology, People s Hospital, Henan Province, China
J Hematol Oncol 5:64. 2012.... - Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual MeetingJiangning Zhao
Department of Hematology, Zhongshan Hospital of Xiamen University, Xiamen 361004, China
Cancer Cell Int 12:38. 2012..In this review, new combination regimens reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma... - A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndromeGuoqing Wei
Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
J Hematol Oncol 4:46. 2011..Randomized controlled trials are strongly recommended to evaluate its efficacy and safety in comparison with the current standard treatment... - First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinibGuoqing Wei
Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, PR China
J Hematol Oncol 3:47. 2010..This review compares and contrasts the three FDA approved first line TKI agents... - Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib MesylateDelong Liu
New York Medical College and Zalmen A Arlin Cancer Institute, Room 250, Munger Pavilion, Valhalla, NY 10595, USA
Leuk Res 28:S61-3. 2004.... - Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institutionKaren Seiter
Zalmen A Arlin Cancer Institute and New York Medical College, New York 10595, USA
Leuk Lymphoma 47:425-32. 2006..Use of a once-daily cytarabine regimen resulted in almost no neurotoxicity and allowed for administration of consolidation in the outpatient setting... 
t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosisJiahuai Tan
Department of Medicine, Mount Vernon Hospital, Mount Vernon, NY, USA
Cancer Invest 27:718-22. 2009..A review of the literature appears to indicate that CML patients with this translocation tend to have an aggressive course and poor outcome. Additional 3-way chromosome translocations associated with CML are also reviewed...- Recent advances and novel agents for gastrointestinal stromal tumor (GIST)Gurpreet Lamba
Division of Oncology Hematology, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
J Hematol Oncol 5:21. 2012..A series of investigations and trials are underway to develop novel and effective ways to treat patients with GIST. In this review, we discuss the highlights of recent advances and novel agents for GIST therapy... - Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsJiahuai Tan
Department of Medicine, The Mount Vernon Hospital, Mount Vernon, NY 10550, USA
J Hematol Oncol 3:5. 2010..This review focuses on recent development in clinical trials testing HDAC inhibitors as anti-tumor agents... - Deficient histone acetylation in acute leukemia and the correction by an isothiocyanateLiyun Xiao
Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China
Acta Haematol 123:71-6. 2010.... - Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathwaysQuanyi Lu
Division of Hematology Oncology, New York Medical College, Valhalla, NY 10595, USA
J Hematol Oncol 1:6. 2008..We conclude that PHI has dual epigenetic effects on p16 hypomethylation and histone hyperacetylation in myeloma cells and targets several critical processes of myeloma proliferation... - Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastimMuhammad Arshad
Department of Medicine, New York Medical College, Valhalla, NY, USA
J Clin Oncol 23:8533-4. 2005 - P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemiaShundong Cang
Division of Hematology Oncology, New York Medical College, Valhalla, NY 10595, USA
J Hematol Oncol 1:15. 2008..This communication reviews the clinical importance of P-loop mutations and the efficacy of the currently available TKIs against them... - Evaluation of temozolomide in patients with myelodysplastic syndromeKaren Seiter
Zalmen A Arlin Cancer Institute, Department of Medicine, New York Medical College, Valhalla, New York, USA
Leuk Lymphoma 45:1209-14. 2004..An unusual finding was the development of leukocytoclastic vasculitis in 4 patients. There were no formal responses to therapy. The current schedule of temozolomide is not efficacious in patients with myelodysplastic syndrome... - Current management and novel agents for malignant melanomaByung Lee
Division of Hematology and Oncology, New York Medical College and Westchester Medical Center, Valhalla, New York 10595, USA
J Hematol Oncol 5:3. 2012..This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy... - Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantationArunabh Sekhri
Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
Leuk Res 33:1291-3. 2009..Currently we present two patients who relapsed 16 and 24 years after allogeneic bone marrow transplantation, respectively. These patients emphasize the need for long term follow-up of such patients... - Prospective evaluation of 2009 H1N1 influenza A in patients admitted with fever to an oncology unitKaren Seiter
Department of Medicine, New York Medical College, Valhalla, New York 10595, USA
Infect Control Hosp Epidemiol 32:815-7. 2011..However, early antiviral intervention could have contributed to a favorable outcome... - Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlightsXiongpeng Zhu
Department of Hematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, 362000, China
J Hematol Oncol 3:17. 2010..This review also summarizes the updates of the clinical trials on novel agents including voreloxin, AS1413, behenoylara-C, ARRY520, ribavirin, AZD1152, AZD6244, and terameprocol (EM-1421) from the 2009 ASH annual meeting... - New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancerShundong Cang
Division of Hematology Oncology, New York Medical College, Valhalla, NY 10595, USA
J Hematol Oncol 2:22. 2009..In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer... - Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndromeKaren Seiter
Zalmen A Arlin Cancer Institute, New York Medical College, Valhalla, NY 10595, USA
Leuk Lymphoma 46:1091-5. 2005..We propose that lack of WRN resulted in increased sensitivity of the patient's cells to the toxicity of chemotherapy... - PET scan-positive cat scratch disease in a patient with T cell lymphoblastic lymphomaWoondong Jeong
Arlin Cancer Institute and New York Medical College, Valhalla, NY 10595, USA
Leuk Res 29:591-4. 2005..This was pathologically proven to be cat scratch disease. This case suggests that in the immunocompromised patients who had history of lymphoma, infectious etiology should be ruled out for PET scan-positive lymphadenopathy... - Reversal in multidrug resistance by magnetic nanoparticle of Fe3O4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cellsBaoan Chen
Department of Hematology, Zhongda Hospital, Southeast University, Nanjing, China
Int J Nanomedicine 3:277-86. 2008..We propose that Fe3O4-MNPs loaded with ADM and Tet probably have synergetic effect on reversal in multidrug resistance... - Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cellsXudong Ma
Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
Int J Oncol 28:1287-93. 2006..The results revealed a potential selective effect of isothiocyanates to inhibit the growth of malignant cells... - Phase I study of temozolomide in relapsed/refractory acute leukemiaKaren Seiter
Department of Medicine, Zalmen A Arlin Cancer Institute, Munger Pavilion Room 250, New York Medical College, Valhalla, NY 10595, USA
J Clin Oncol 20:3249-53. 2002..To determine the dose-limiting toxicity and maximum-tolerated dose of temozolomide in patients with acute leukemia... - Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrestJen Wei Chiao
Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
Carcinogenesis 25:1403-8. 2004..PEITC-NAC may prevent initiation of carcinogenesis and modulate the post-initiation phase by targeting cell cycle regulators and apoptosis induction... - Clinical advances in hypomethylating agents targeting epigenetic pathwaysS Cang
Department of Oncology, People s Hospital, Henan Province, Zhengzhou, China
Curr Cancer Drug Targets 10:539-45. 2010..In this review we summarize recent clinical developments on novel hypomethylating agents and new regimens from clinical trials for epigenetic therapy of cancer... - Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer preventionLonggui Wang
Division of Medical Oncology, Mount Sinai Medical Center, New York, NY 10029, USA
Int J Oncol 24:187-92. 2004..The potential of SFN, as an active dietary factor to inhibit initiation and post-initiation of prostate cancer carcinogenesis is discussed... - A geometric approach to determine association and coherence of the activation times of cell-cycling genes under differing experimental conditionsDelong Liu
Biostatistics Branch, MD:A3-03, National Institute of Environmental Health Sciences, National Institutes of Health, PO Box 12233, Research Triangle Park, NC 27709, USA
Bioinformatics 20:2521-8. 2004..Our proposed methodology is illustrated by applying it to a HeLa cell-cycle gene-expression data... - Severe imatinib-associated muscle edema in patients with chronic myelogenous leukemia and marked leukocytosisSivamurthy Kyathari
Leuk Lymphoma 49:1002-4. 2008 - Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestineSamir Patel
Leuk Lymphoma 48:1032-3. 2007 - p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesisYan Xiong
Endocrine Biology Program, Center for Integrated Genomics, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709, USA
J Biol Chem 282:4975-82. 2007..Together, we have identified an inhibitory role for p38 in the transcription of central lipogenic genes, SREBPs, and PGC-1beta and hepatic lipogenesis... - Analysis of variation of amplitudes in cell cycle gene expressionDelong Liu
CIIT Ceters for Health Research, 6 Davis Drive, Research Triangle Park, NC 27709, USA
Theor Biol Med Model 2:46. 2005..We investigated whether different cell-arresting methods have impacts on the maximum expression levels (amplitudes) of a cell cycle related gene... - Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentialsLu-Lu Lu
National Engineering Research Center of Cell Products, AmCellGene Co. Ltd
Haematologica 91:1017-26. 2006..The comparative study indicates that UC is an excellent alternative to BM as a source of MSC for cell therapies...